27-Feb-2026
Business Wire (Fri, 27-Feb 7:30 AM ET)
ImmunityBio’s Trial: ANKTIVA Plus BCG Shows Promising Results in Bladder Cancer Study
Market Chameleon (Thu, 26-Feb 2:44 AM ET)
Business Wire (Thu, 26-Feb 7:30 AM ET)
Market Chameleon (Tue, 24-Feb 6:17 AM ET)
Business Wire (Mon, 23-Feb 4:15 PM ET)
Biotech Breakthroughs, Big Buyouts, Immunotherapy Momentum, and a Media Megamerger
Globe Newswire (Mon, 23-Feb 9:36 AM ET)
Market Chameleon (Mon, 23-Feb 3:12 AM ET)
ImmunityBio GAAP EPS of -$0.06, revenue of $38.2M
Seeking Alpha News (Mon, 23-Feb 8:06 AM ET)
Business Wire (Mon, 23-Feb 7:00 AM ET)
Business Wire (Fri, 20-Feb 8:30 AM ET)
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
Immunitybio trades on the NASDAQ stock market under the symbol IBRX.
As of February 27, 2026, IBRX stock price climbed to $9.78 with 26,681,312 million shares trading.
IBRX has a beta of 1.79, meaning it tends to be more sensitive to market movements. IBRX has a correlation of 0.07 to the broad based SPY ETF.
IBRX has a market cap of $9.63 billion. This is considered a Mid Cap stock.
Last quarter Immunitybio reported $38 million in Revenue and -$.06 earnings per share. This beat revenue expectation by $777,000 and exceeded earnings estimates by $.03.
In the last 3 years, IBRX traded as high as $12.43 and as low as $1.21.
The top ETF exchange traded funds that IBRX belongs to (by Net Assets): XBI, VTI, IWM, VB, VBK.
IBRX has outperformed the market in the last year with a price return of +242.0% while the SPY ETF gained +18.5%. IBRX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +359.2% and +64.5%, respectively, while the SPY returned +1.2% and +0.6%, respectively.
IBRX support price is $8.71 and resistance is $10.39 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IBRX shares will trade within this expected range on the day.
